These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 24356920)

  • 1. Efficacy of tegafur-uracil (UFT) administration in castration-resistant prostate cancer patients with a history of both alternative antiandrogen therapy and estramustine phosphate sodium hydrate therapy.
    Hayakawa N; Matsumoto K; Sato A; Sakamoto H; Ezaki T; Maeda T; Ninomiya A; Nakamura S
    Int Urol Nephrol; 2014 Jun; 46(6):1123-9. PubMed ID: 24356920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of estramustine phosphate sodium hydrate (EMP) monotherapy in castration-resistant prostate cancer patients: report of 102 cases and review of literature.
    Matsumoto K; Tanaka N; Hayakawa N; Ezaki T; Suzuki K; Maeda T; Ninomiya A; Nakamura S
    Med Oncol; 2013 Dec; 30(4):717. PubMed ID: 24005812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of oral uracil/tegafur (UFT) therapy for patients with hormone refractory prostate cancer.
    Miyake H; Hara I; Yamazaki H; Eto H
    Oncol Rep; 2005 Sep; 14(3):673-6. PubMed ID: 16077973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective and Safe Administration of Low-Dose Estramustine Phosphate for Castration-Resistant Prostate Cancer.
    Inoue T; Ogura K; Kawakita M; Tsukino H; Akamatsu S; Yamasaki T; Matsui Y; Segawa T; Sugino Y; Kamoto T; Kamba T; Tanaka S; Ogawa O
    Clin Genitourin Cancer; 2016 Feb; 14(1):e9-e17. PubMed ID: 26433627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral combination of cyclophosphamide, uracil plus tegafur and estramustine for hormone-refractory prostate cancer.
    Nishimura K; Nonomura N; Ono Y; Nozawa M; Fukui T; Harada Y; Imazu T; Takaha N; Sugao H; Miki T; Okuyama A
    Oncology; 2001; 60(1):49-54. PubMed ID: 11150908
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
    Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
    BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Low-Dose Estramustine Phosphate Monotherapy in Castration-Resistant Prostate Cancer Patients].
    Fukui T; Nakamura K; Sakatani T; Atsuta T; Kato T; Fukumoto T; Ito M; Inoue K; Terai A
    Hinyokika Kiyo; 2017 Feb; 63(2):57-62. PubMed ID: 28264534
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and Prognostic Factors of Estracyt ® in Patients with Castration-Resistant Prostate Cancer (CRPC) : From the Data Analysis of Estracyt ® Special Drug Use Investigation].
    Murachi K; Kumagai T; Masuda T; Nakanishi T; Tanaka S; Tajima K; Takebe Y; Oda T
    Hinyokika Kiyo; 2016 Jun; 62(6):295-306. PubMed ID: 27452492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine plus uracil/tegafur therapy for prostate cancer.
    Ono Y; Ohshima S; Takahashi Y; Kuriyama M; Kawada Y; Shimizu H
    Oncology (Williston Park); 1999 Jul; 13(7 Suppl 3):120-4. PubMed ID: 10442379
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Third-line hormonal therapy to treat prostate cancer relapse after initial and second-line hormonal therapy: report of 52 cases and literature review.
    Matsumoto K; Hagiwara M; Hayakawa N; Tanaka N; Ito Y; Maeda T; Ninomiya A; Nagata H; Nakamura S
    Asian Pac J Cancer Prev; 2014; 15(8):3645-9. PubMed ID: 24870772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding prostate-specific antigen dynamics in monitoring metastatic castration-resistant prostate cancer: implications for clinical practice.
    Mizokami A; Izumi K; Konaka H; Kitagawa Y; Kadono Y; Narimoto K; Nohara T; Bahl AK; Namiki M
    Asian J Androl; 2017; 19(2):143-148. PubMed ID: 27270339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bicalutamide 150 mg as secondary hormonal therapy for castration-resistant prostate cancer.
    Qian SB; Shen HB; Cao QF; Zhang L; Chen YF; Qi J
    Int Urol Nephrol; 2015 Mar; 47(3):479-84. PubMed ID: 25665794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC).
    Vestermark LW; Jacobsen A; Qvortrup C; Hansen F; Bisgaard C; Baatrup G; Rasmussen P; Pfeiffer P
    Acta Oncol; 2008; 47(3):428-33. PubMed ID: 18348002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
    Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
    Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of Uracil-tegafur (UFT) in patients with advanced biliary tract carcinoma.
    Ikeda M; Okusaka T; Ueno H; Morizane C; Furuse J; Ishii H
    Jpn J Clin Oncol; 2005 Aug; 35(8):439-43. PubMed ID: 16024530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pharmacokinetics and a phase I study of tegafur-uracil enterogranules in cancer patients].
    Kamiya O; Hoshino A; Ohara K; Nagata K; Kojima T; Sugihara T; Yamada M; Suzuki M; Kimura K; Fujii S
    Gan To Kagaku Ryoho; 1983 Dec; 10(12):2565-72. PubMed ID: 6418079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Progress in oral anti-cancer drug therapy for urological cancer].
    Tsukamoto S; Akaza H
    Gan To Kagaku Ryoho; 1999 Feb; 26(3):308-14. PubMed ID: 10065093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of oral uracil/tegafur plus leucovorin in patients with hormone-refractory prostate carcinoma.
    Bhandari MS; Pienta KJ; Fardig J; Olson K; Smith DC
    Cancer; 2006 Apr; 106(8):1715-21. PubMed ID: 16534795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative UFT adjuvant and the risk factors for recurrence in renal cell carcinoma: a long-term follow-up study. Kyushu University Urological Oncology Group.
    Naito S; Kumazawa J; Omoto T; Iguchi A; Sagiyama K; Osada Y; Hiratsuka Y
    Int J Urol; 1997 Jan; 4(1):8-12. PubMed ID: 9179659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer.
    Hatano K; Nishimura K; Nakai Y; Yoshida T; Sato M; Kawashima A; Mukai M; Nagahara A; Uemura M; Oka D; Nakayama M; Takayama H; Shimizu K; Meguro N; Tanigawa T; Yamaguchi S; Tsujimura A; Nonomura N
    Int J Clin Oncol; 2013 Aug; 18(4):704-10. PubMed ID: 22688162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.